Research articlePublished 5 Jul 2019
Challenges of Hepatotoxicity Associated with Isoniazid Preventive Therapy among People Living with HIV in Eritrea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background Isoniazid preventive therapy (IPT) is an intervention recommended by the WHO for prophylaxis of Tuberculosis (TB) in people living with HIV (PLWH) and reported as generally safe with little risk of hepatotoxicity. Following its introduction in Eritrea in 2014, IPT related hepatotoxicity and fatality have been frequently reported to the Eritrean Pharmacovigilance Centre. The aim of this study is, therefore, to quantify the risk of hepatotoxicity, evaluate the effectiveness of close laboratory monitoring, assess the causal relationship of IPT and hepatotoxicity, identify possible risk factors and assess preventability of Isoniazid-induced hepatotoxicity in PLWH. Methods This was an observational cohort study of PLWH on IPT enrolled from three Antiretroviral therapy (ART) Clinics in Asmara, Eritrea, between August 2016 and February 2017. Causality and preventability of the cases was assessed using Naranjo probability scale and P-method respectively. Results Of the 360 eligible patients, 56 were identified with hepatotoxicity with an incidence rate of cases per 1000 person-months with a median time to reaction onset of 34 days. About 41% of the cases developed severe or very severe hepatotoxicity following initiation of IPT. INH was terminated in 78.6% of the cases and reaction abated in 84.1% (37/44) following withdrawal of INH. Besides, ART was discontinued in 42.5% of the cases due to hepatotoxicity. In majority of the cases (87.5%), the causal relationship was found to be ‘probable’ and in 82.1% hepatotoxicity was not preventable. Conclusion The incidence rate of INH-related hepatotoxicity is very high with a short time to reaction onset and the occurrence of severe/ very severe hepatotoxicity was unavoidable in substantial number of patients; making risk minimization plan and IPT deployment challenging.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAdvances in Pharmacoepidemiology and Drug Safety
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Mulugeta Russom”
- BylineArticles whose byline prints “Araia Berhane”
- BylineArticles whose byline prints “Merhawi Debesai”
- BylineArticles whose byline prints “Hagos Andom”
- BylineArticles whose byline prints “Dawit Tesfai”
- BylineArticles whose byline prints “Zenawi Zeremariam”
- BylineArticles whose byline prints “Selamawit Gebrehiwet”
- BylineArticles whose byline prints “Nighisty Tesfamichael”
